They’re additionally in talks with regulatory authorities about testing a vaccine modified to guard particularly in opposition to the extremely transmissible new variant present in South Africa and elsewhere, often called B.1.351, as a second arm of the identical research.
The businesses imagine their present two-dose vaccine will work in opposition to the South African variant in addition to one present in the UK and elsewhere. However the research will enable the vaccine makers to be ready if and when extra safety is important, they mentioned.
“The speed of mutations within the present virus is larger than anticipated,” Pfizer Chief Scientific Officer Mikael Dolsten mentioned in an interview.
“It is a affordable chance that we might find yourself with